Compumedics Limited provided unaudited group earnings guidance for the fiscal year ended June 30, 2018. The company expected sales for the twelve months to 30 June 2018 are approximately $36 million with sales in Asia up by a further 15% approximately over the same period last year. This is compared to sales of $34 million for the same period last year. Sales for the twelve months to 30 June 2018 are lower than previous guidance due to delays in receiving several significant new sales orders in the Company's US business. Underlying EBITDA is expected to be between $2.5 million and $3.5 million. The transition phase of the Company's US business has taken longer than expected, given the competitive nature of the US market, which has resulted in lower than forecasted sales for the US business in FY18, which has impacted on the second half FY18. This is despite the US clinical business growing by 10%. The Company continues to believe the changes made in the US business will generate further growth in FY19.